Table 1.
Baseline characteristics
| Characteristic | Value |
|---|---|
| Age (years) | 67.0 ± 9.9 |
| Male gender | 17 (94.4) |
| Ischemic cardiomyopathy | 10 (55.6) |
| NYHA III/IV | 7 (38.9) |
| MLWHF questionnaire score | 36.6 ± 23.5 |
| 6MWT distance (m) | 316 ± 128 |
| NT‐proBNP (ng/ml) | 1108.1 ± 767.3 |
| Hemoglobin (g/L) | 139.4 ± 13.8 |
| eGFR (ml/min/1.73m2) | 69.1 ± 21.0 |
| Paced QRS duration (ms) | 154 ± 30 |
| Left bundle branch block | 15 (83.3) |
| CT Dose Length Product (mGycm) | 1196 (1069–2049) |
| Atrial fibrillation | 9 (50) |
| RV pacing burden (%) | 60.0 ± 43.7 |
| RV pacing burden >40% | 18 (100) |
| ACE inhibitor/ARB/Sacubitril and Valsartan | 18 (100) |
| Beta‐blocker | 16 (88.9) |
| Aldosterone antagonist | 12 (66.7) |
| Loop diuretic | 9 (50) |
| Antiarrhythmic | 4 (22.2) |
| Antiplatelet | 7 (38.9) |
Note: Values are presented as mean ± SD, median (IQR) or as n (%).
Abbreviations: 6MWT, 6‐min walk test; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CT, computed tomography; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MLWHF, Minnesota living with heart failure; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.